Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × Lung Neoplasms × Blood Cell Count × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Leukemia 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Paraproteinemias 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myeloid 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Neoplasms 1

Interventions

Surveys and Questionnaires 19 Blood Specimen Collection 18 Gene Expression Profiling 12 Radiotherapy 11 Magnetic Resonance Spectroscopy 9 Surgical Procedures, Operative 8 Specimen Handling 8 Immunohistochemistry 8 Polymerase Chain Reaction 7 Drug Therapy 7 pembrolizumab 6 Observation 6 Amplified Fragment Length Polymorphism Analysis 6 Tomography, X-Ray Computed 5 Reverse Transcriptase Polymerase Chain Reaction 5 Psychiatric Rehabilitation 5 Liquid Biopsy 5 Interviews as Topic 5 Carboplatin 5 Bronchoscopy 5 Thoracic Surgery, Video-Assisted 4 Therapeutics 4 Paclitaxel 4 Microarray Analysis 4 Ipilimumab 4 Biopsy 4 Bevacizumab 4 osimertinib 3 durvalumab 3 atezolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03749512 2018-11-21

NLCR in Prediction of the Grade of Lung Tumor.

Medical University of Silesia

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡